News | February 25, 2026
Formosa strikes exclusive deal with Arrotex to launch eye surgery drug in Australia & NZ
The innovative eyedrop targets inflammation and pain following ocular surgery
The innovative eyedrop targets inflammation and pain following ocular surgery
NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
The funding comes under the AHG Catalysing Innovation Awards, part of the Addiction Healthcare Goals programme led by the Office for Life Sciences
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major
The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns
Subscribe To Our Newsletter & Stay Updated
